Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dementias Platform UK continues to expand as Cambridge Cognition, a global leader in cognitive assessment for clinical trials, upgrades its current position as associate partner to become full partner.

Camcog_large_logo_rgb_1200_dpi.jpg

As leaders in the field of cognitive assessment for clinical trials and health research, Cambridge Cognition is a fitting partner for Dementias Platform UK (DPUK). DPUK is a public-private partnership, funded by the Medical Research Council to accelerate the development of treatments for dementia through the unique power of long-term population studies, known as ‘cohorts’. Along with DPUK’s seven other industry partners, each with their own specialism, Cambridge Cognition will help drive the development of high quality resources for dementia researchers.

 

Effective, fine-grained assessment of people who may be at the earliest stages of the disease, is just one part of the research effort into scientists’ developing understanding of dementia. Cambridge Cognition’s expertise and technical resource in this field will benefit the 50+ cohort studies that DPUK already works with, enabling them to enhance their records, thereby improving an already exceptionally high-quality data resource for scientific research and trials into dementia. 

New opportunities for DPUK cohort studies

Cambridge Cognition has developed the well-regarded ‘CANTAB software’ – an online assessment tool to measure abilities, such as memory, attention, planning and decision-making, all aspects of a person’s thinking that will deteriorate as dementia progresses. Measuring the pace and variation of this change is essential for scientists who are involved in testing new treatments or in research. Carrying out such testing can often be costly and time consuming, making it out of reach for smaller studies which may lack the funding or the scientists to run physical tests.

 

Thanks to Cambridge Cognition, DPUK’s population or ‘cohort’ studies – already rich and valuable sources of data for the scientific community – will be able to run cognitive tests on Cambridge Cognition’s cloud-based platform. By enabling the study participants to take the tests at home on their own computer or tablet, and by allowing the cohort scientists as much or as little control over the process as they’d like, DPUK is able to further enhance cohorts’ immensely valuable historic data, bringing it up-to-date and relevant for today’s studies into treatments for dementia.

 

Cambridge Cognition exemplify the value of Dementias Platform UK – by joining us and offering this valuable service to cohorts, better data can be made available to scientists around the world. This will speed up our search for new understanding of and treatments for dementias – an invaluable outcome for all.’

 

- Professor John Gallacher, Director, Dementias Platform UK

 

Detailed data kept secure for research

Participant test results will be held on Cambridge Cognition’s secure platform and delivered to DPUK at agreed intervals. These data, which are all anonymised and stored on DPUK servers at the highest information security standards, will then be made available to researchers, approved on a case-by-case basis, to use in their studies into dementia.

 

Looking further ahead, there is the possibility of DPUK cohorts working with Cambridge Cognition to develop new tests, according to an individual cohort study’s needs.

 

Cambridge Cognition is already working with DPUK on the Deep and Frequent Phenotyping Study.